ArticleNature2023
Histone demethylase KDM5D upregulation drives sex differences in colon cancer.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed
22.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 135 citations in OpenAlex.
- Sex-Specific Proteomic Profiling Identifies Pregnancy Zone Protein as a Complement-Linked Marker of Adverse Prognosis in Esophageal Adenocarcinoma.International journal of cancer · 2026Article
- Multiplatform single-cell and spatial transcriptomics reveal sex-specific malignant states and architecture in male breast cancer.Science advances · 2026Article
- Inhibition of KDM5A/B promotes antitumor innate immune responses in HHV-8/KSHV-positive B-cell lymphomas.Npj viruses · 2026Article
- Sex of central neurons controls intestinal niche signalling to drive sex differences in stem cell activity and cancer susceptibility.Nature communications · 2026Article
- Beyond sex determination: the Y chromosome in male cancers.Nature reviews. Cancer · 2026Review
- Review
- Multi-omics profiling unveils biological and clinical insights into pulmonary sarcomatoid carcinoma.Cell reports. Medicine · 2026Article
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- Primary Tumor-Associated Loss of the Y Chromosome and Clinical Outcome in Metastatic Colorectal Cancer.Genes, chromosomes & cancer · 2026Article
- Loss of chromosome Y in hematopoietic cells: mechanisms and implications for human disease.MedScience · 2026Review
- Methyltransferase MGMT upregulation drives metastasis by activating epithelial-mesenchymal transition in KRAS mutant colon cancer.Cell death & disease · 2026Article
- Molecular mechanisms and clinical impacts of sex differences in urologic cancers.Discover oncology · 2026Review
- Review
- Noncanonical role of KDM5C in conferring bortezomib resistance via the PERK‒Nrf2 axis in multiple myeloma.Cell death & disease · 2026Article
- The JMJD family histone demethylases: structure, mechanism of action, diseases and therapeutic targets.Molecular biomedicine · 2026Review
- Loss of the Y Chromosome in Oral Potentially Premalignant Disorders Predicts Malignant Progression: An Integrative Cross-Species Multi-Cohort Bioinformatic Study.Head & neck · 2026Article
- Harnessing PDX and PDX 2.0: the next-generation paradigm for precision oncology and translational breakthroughs.Molecular cancer · 2026Review
- Risk evaluation for second primary malignancy development in individuals with colorectal adenocarcinoma: a population-based investigation.World journal of surgical oncology · 2026Article
- Predicting disease-specific histone modifications and functional effects of non-coding variants by leveraging DNA language models.Genome biology · 2026Article
- Sexual dimorphism in cancer: molecular mechanisms and precision oncology perspectives.Biology of sex differences · 2026Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
23 authors at 1 institution in 2 countries.
Jiexi LiDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1508-5732
Zhengdao LanDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wenting LiaoDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
James W HornerTRACTION Platform, Division of Therapeutics Discovery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xueping XuTRACTION Platform, Division of Therapeutics Discovery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jielin LiuDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yohei YoshihamaDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shan JiangTRACTION Platform, Division of Therapeutics Discovery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hong Seok ShimDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Max SlotnikDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kyle A LaBellaDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-0473-9262
Chang-Jiun WuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8350-6397
Kenneth DunnerDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wen-Hao HsuDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rumi LeeDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Isha KhanduriDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christopher TerranovaDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-3674-7013
Kadir AkdemirDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Deepavali ChakravartiDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiaoying ShangDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Denise J SpringDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-4593-0901
Y Alan WangDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8272-2450
Ronald A DePinhoDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. RDePinho@mdanderson.org.ORCID 0000-0002-5625-577X
The University of Texas MD Anderson Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8MConvalescent Plasma to Limit Coronavirus Associated ComplicationsUL1TR003167 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KARP, DANIEL D, MCPHERSON, DAVID D · 2019 to 2023
$45.3MNRSA Training CoreTL1TR003169 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CHANDRA, JOYA, FROST, JEFFREY A. · 2019 to 2023
$3.7MGenetics and Biology of Metastatic Colorectal CancerR01CA231360 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2018 to 2022
$1.8MTraining Grant in Cancer BiologyT32CA186892 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 2016 to 2020
$1.1MSuper-Resolution OMX MicroscropeS10RR029552 · NCRR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ZAL, TOMASZ · 2011 to 2011
$1.0MNovaSeq6000S10OD024977 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUFF, VICKI · 2018 to 2018
$995kOncogenic Kras drives stromal adipogenesis to promote colorectal cancer (CRC) progressionK00CA274661 · NCI · STANFORD UNIVERSITY · PI Wen-Hao Hsu · 2024 to 2026
$297kOncogenic Kras drives stromal adipogenesis to promote colorectal cancer (CRC) progressionF99CA274661 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HSU, WEN-HAO · 2022 to 2023
$84kNCATS NIH HHS TL1 TR003169NCATS NIH HHS UL1 TR003167NCI NIH HHS F99 CA274661NCI NIH HHS K00 CA274661NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA231360NCI NIH HHS T32 CA186892NCRR NIH HHS S10 RR029552NIH HHS S10 OD024977
Abstract
Sex exerts a profound impact on cancer incidence, spectrum and outcomes, yet the molecular and genetic bases of such sex differences are ill-defined and presumptively ascribed to X-chromosome genes and sex hormones
Indexed as
Colorectal NeoplasmsHistone DemethylasesMinor Histocompatibility AntigensSex CharacteristicsAdenomatous Polyposis Coli ProteinAnimalsCD8-Positive T-LymphocytesDisease Models, AnimalFemaleHumansMaleMiceMice, TransgenicProto-Oncogene Proteins p21(ras)STAT4 Transcription FactorTumor Suppressor Protein p53Adenomatous Polyposis Coli Proteinadenomatous polyposis coli protein, mouseAPC protein, humanHistone DemethylasesKDM5D protein, humanKdm5d protein, mouseKRAS protein, humanMinor Histocompatibility AntigensProto-Oncogene Proteins p21(ras)STAT4 protein, humanStat4 protein, mouseSTAT4 Transcription FactorTP53 protein, humanTrp53 protein, mouseTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.